On Sunday, Kura Oncology Announced Updated Clinical Data From The KOMET-001 Phase 1/2 Trial Of Ziftomenib, Including Significant Clinical Activity In Patients With Heavily Pretreated And Co-Mutated Relapsed/Refractory NPM1-mutant Acute Myeloid Leukemia
Portfolio Pulse from Benzinga Newsdesk
Kura Oncology announced updated clinical data from the KOMET-001 Phase 1/2 trial of Ziftomenib, showing significant clinical activity in patients with heavily pretreated and co-mutated relapsed/refractory NPM1-mutant acute myeloid leukemia.
June 12, 2023 | 8:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kura Oncology's KOMET-001 Phase 1/2 trial of Ziftomenib shows promising results in NPM1-mutant acute myeloid leukemia patients.
The positive results from the KOMET-001 Phase 1/2 trial of Ziftomenib indicate significant clinical activity in NPM1-mutant acute myeloid leukemia patients. This is likely to have a positive impact on Kura Oncology's stock price in the short term as it demonstrates the potential of their product in treating this specific type of leukemia.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100